Sugi Predict

Sugi Predict / Compounds / SCHEMBL3409818

SCHEMBL3409818

SCHEMBL3409818

CC(c1ccc2nccn2c1)c1cnc2ccc(Cl)nn12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 7/20 0.37
▸ DYRK2 Q92630 6/20 0.37
▸ CCNA2 P20248 5/20 0.37
▸ CDK2 P24941 5/20 0.37
▸ CDK5 Q00535 5/20 0.37
▸ CDK5R1 Q15078 5/20 0.37
▸ DYRK1B Q9Y463 5/20 0.37
▸ DYRK3 O43781 4/20 0.37
▸ MET P08581 5/20 0.37
▸ NQO2 P16083 1/20 0.37
▸ TNF P01375 2/20 0.36
▸ S1PR3 Q99500 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ CCNT1 O60563 2/20 0.34
▸ CDK9 P50750 2/20 0.34
▸ KEAP1 Q14145 1/20 0.34
▸ JAK2 O60674 1/20 0.33
▸ TGFBR1 P36897 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3411255 0.85 DYRK1A (0.40) DYRK1ADYRK2CCNA2CDK2CDK5
Bromoethane SCHEMBL3414106 0.81 DYRK1A (0.35) DYRK1ADYRK2CCNA2CDK2CDK5
SCHEMBL3414108 0.80 DYRK1A (0.34) DYRK1ADYRK2CCNA2CDK2CDK5
SCHEMBL1661476 0.79 MET (0.54) DYRK1ADYRK1BMETNQO2
SCHEMBL1661477 0.79 MET (0.54) DYRK1ADYRK1BMETNQO2
SCHEMBL1659889 0.79 MET (0.54) DYRK1ADYRK1BMETNQO2
SCHEMBL3434280 0.77 MET (0.46) DYRK1BMETJAK2TGFBR1
SCHEMBL3434297 0.74 MET (0.45) METNQO2JAK2
SCHEMBL22159024 0.74 TNF (0.50) DYRK1ADYRK2CCNA2CDK2CDK5
SCHEMBL22185649 0.74 TNF (0.49) DYRK1ADYRK2CCNA2CDK2CDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264406-A1 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES NOVARTIS AG 2009-10-22 — — US claimed
US-8822468-B2 3-Methyl-imidazo[1,2-b]pyridazine derivatives NOVARTIS AG (CH) 2014-09-02 — — US disclosed
US-8822468-B2 3-Methyl-imidazo[1,2-b]pyridazine derivatives NOVARTIS AG (CH) 2014-09-02 — — US disclosed
US-8822468-B2 3-Methyl-imidazo[1,2-b]pyridazine derivatives NOVARTIS AG (CH) 2014-09-02 — — US disclosed
EP-2265614-A1 IMIDAZO [1,2-B]PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE Novartis AG (CH) 2010-12-29 — — EP disclosed
US-20090264406-A1 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES NOVARTIS AG 2009-10-22 — — US disclosed
US-20090264406-A1 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES NOVARTIS AG 2009-10-22 — — US disclosed
US-20090264406-A1 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES NOVARTIS AG 2009-10-22 — — US disclosed
WO-2009106577-A1 IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE NOVARTIS AG (CH) 2009-09-03 — — WO disclosed
WO-2009106577-A1 IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE NOVARTIS AG (CH) 2009-09-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264406-A1 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES MET, ERBB2, ALK DYRK1A 560/4885DYRK2 457/4885CCNA2 1257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.